- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02191306
Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy
Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy
Intro:
It is well known that HIV treated with antiretroviral drugs increases the risk for coronary artery disease. Studies have documented this with various methods including analyzing the effects of retroviral therapy on cardiac risk factors such as diabetes, lipids and hypertension. Still other studies have looked at carotid and brachial artery intimal thickness. Our study, then, aims to evaluate the relationship between HIV medications and coronary atherosclerosis using a novel method. Coronary artery CT angiography is a relatively new diagnostic procedure to evaluate heart disease in cardiac patients. We will apply this test to HIV patients on longstanding antiretroviral therapy to directly examine their coronary arteries to assess heart disease.
Hypothesis:
We hypothesize that HIV patients on antiretroviral therapy will have increased coronary artery disease compared to the general population.
Methods:
This project will be conducted in collaboration between Florida Heart Center and Associates in infectious Disease - two communities based infectious disease and cardiology practices. We will identify all the HIV positive patients seen within a 1 month timeframe at the infectious disease office. These patients will then be filtered by our exclusion/inclusion criteria. After obtaining informed consent, we will draw blood from each patient to gather lab values such as A1C, cholesterol, inflammatory markers, and other markers associated with coronary artery disease. Each enrolled patient will then schedule and receive a 64 slide coronary CTA at Florida Heart Center. The results of the CTA scans will be categorized in mild, moderate, and severe coronary artery disease. The data, then, will consist of the parameters measured on blood work, and the results of the coronary CTA.
Inclusion Criteria:
1. Patients aged 35 to 50 with HIV and on retroviral therapy for at least 5 years.
Exclusion Criteria:
1. Patients with prior documented coronary artery disease, heart attack, stent placement, or heart surgery.
Statistical Analysis:
We will conduct a multivariate analysis on the cardiac risk factors taken from patient history and the bloodwork (diabetes, lipids etc) to correlate them with the results of the CTA. We will also conduct basic analysis to support our hypothesis that long term antiretroviral therapy increases coronary artery disease.
Funding:
The bloodwork and CTA tests ordered in this study will be payed for by insurance companies where available. In cases where insurance companies will not pay, Florida Heart Center will pay for the CTA tests and Associates in infectious Disease will fund the bloodwork.
Humans Subjects Protection:
This will be a projective chart review study that will require access to protected health information. Thus, we will seek full IRB approval from the FSU IRB committee with informed consent. An informed consent document will be given to each patient explaining all the risks and benefits of the study in addition to the methods. Recruitment will be done by an office staff or medical assistant not on the research team. After patient recruitment, their medical records will be flagged for study and they will undergo the required testing. At completion of testing, their results will be recorded in the final data sheet, and their medical record will no longer be flagged for study. No identifying data will be recorded in the final data sheet, and the data will be stored in an encrypted excel sheet on a secure password protected personal laptop running antivirus and firewall. Third parties (such as family members) will not have access to any research data regardless of authorizations received from the study subjects. All the test results and labwork performed for the study will go into the patient's individual medical record at their respective offices. Thus, if an authorized third party wishes to view any test results, they can do so via the normal methods at the doctor's office.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Pierce, Florida, United States, 34950
- Associates in Infectious Disease
-
Fort Pierce, Florida, United States, 34950
- Florida Heart Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 35 to 50 with HIV and on retroviral therapy for at least 5 years
Exclusion Criteria:
- Patients with prior documented coronary artery disease, heart attack, stent placement, or heart surgery.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
HIV Positive Patients (Study Group)
|
Non HIV Positive Patients (Control)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calcium Score Measured from CT Angiography
Time Frame: 1 Day
|
Each CT Scan was analyzed and a calcium score was associate with each plaque lesion in the coronary arteries.
This score correlates with the presence of coronary artery disease in the patient.
|
1 Day
|
Increased Inflammatory Markers in Bloodwork
Time Frame: 1 Day
|
The blood work taken from each HIV positive patient was run with a cardiovascular inflammatory marker panel which gave the researchers another measure of coronary artery disease
|
1 Day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased Inflammatory Markers on Lab Panel
Time Frame: 1 Day
|
The blood work taken from each HIV positive patient was run with a cardiovascular inflammatory marker panel which gave the researchers another measure of coronary artery disease
|
1 Day
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, Grinspoon SK. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010 Jan 16;24(2):243-53. doi: 10.1097/QAD.0b013e328333ea9e.
- Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, Harrill D, Tungsiripat M, Adell J, McComsey GA. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009 Oct 1;49(7):1119-27. doi: 10.1086/605578.
- Fitch KV, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, Lo J, Grinspoon SK. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis. 2013 Dec 1;208(11):1737-46. doi: 10.1093/infdis/jit508. Epub 2013 Sep 16.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00000446
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Evaluate the Relationship Between HIV Medications and Coronary Atherosclerosis
-
Centre Hospitalier Universitaire VaudoisSwiss National Science FoundationCompletedRelationship Between Calcimimetic and the RAASSwitzerland
-
Christian Ramos PenafielHospital General de Mexico; Universidad Nacional Autonoma de Mexico; Instituto...CompletedEstablish the Relationship Between Moon and BirthsMexico
-
Assiut UniversityRecruitingThe Relationship Between the Anteroposterior Diameter of the CM and the Gestational Age and GenderEgypt
-
Jingyuan,XuUnknownEvaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDSChina
-
Chun PanUnknownEvaluate the Correlation Between the Level of Mitochondrial DNA in Plasma and the Prognosis of the Patients With ARDS.China
-
CerbaXpertRecruitingEvaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)France
-
Aydin Adnan Menderes UniversityEnrolling by invitationThe Relationship Between TAPSE Value and VolumeTurkey
-
Uskudar UniversityCompletedInvestigate the Relationship Between the Psychosocial Factors Affecting Pain Perception and Physical Activity Levels in Pregnant Women With Lumbopelvic PainTurkey
-
The First Affiliated Hospital of Guangzhou Medical...Completedthe Relationship Between the Tumor Markers and Interstitial Lung Disease PatientsChina
-
Mohammed VI University HospitalCompletedthe Relationship Between Procalcitonin and 30-day Mortality in COVID PatientsMorocco